CA1183776A - Collagen implant containing active ingredient(s) for implantation in bones or soft tissues and process for its manufacture - Google Patents
Collagen implant containing active ingredient(s) for implantation in bones or soft tissues and process for its manufactureInfo
- Publication number
- CA1183776A CA1183776A CA000406019A CA406019A CA1183776A CA 1183776 A CA1183776 A CA 1183776A CA 000406019 A CA000406019 A CA 000406019A CA 406019 A CA406019 A CA 406019A CA 1183776 A CA1183776 A CA 1183776A
- Authority
- CA
- Canada
- Prior art keywords
- active ingredient
- collagen
- implant containing
- sheet
- containing active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
- A61L31/044—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Abstract:
Collagen implant containing active ingredient(s) for im-plantation in bones or soft tissues, whereby the implant is designed in sheet or in rod form, and a process for preparation thereof.
Collagen implant containing active ingredient(s) for im-plantation in bones or soft tissues, whereby the implant is designed in sheet or in rod form, and a process for preparation thereof.
Description
'7~
Collagen Implant Containing Active Ingredient(s) for Implantation in Bones or Soft Tissues and Process for its Manufacture The invention concerns an implant resorbable in the body and 5 containing active ingredients, for implantation in bones and soft tissues. It especially relates to a collagen implant ln the form of a sheet containing active ingredient(s), which optionally c~n be rolled into a rod and which after implan-tation in the bone or tissue gradually releases the ingre-10 dient(s).
It is known that collagen can be used as material which isbioresorbable in the body, for filling defects in bones or in soft tissues.
The use of polyhydroxy acetic acid ester for the manufacture 15 of antibiotic-containing resorbable surgical materials, e.g.
tubes, is known from DE-PS 12 93 396. DE-OS 20 51 ~ des-cribes a combination of an active ingredient with a polylac-tide or of a copolymer of lactide and glycolide units.
The above-mentioned materials are synthetic polymers or co-20 polymers which are decomposed in the body. Such polymers and copolymers have increasingly gained in significance because as fully synthetic products they have readilly re-producible properties and can be prepared in high purity.
;.... .
Materials of the above-mentioned polymers and copolymers are also used as synthetic resorbable suture materials.
For many years collagen has been known as a resorbable ma-terial and has been used hemostatically, especially during 5 and a~ter surgical operations or to fill body cavities or to cover wounds. There have always been certain problems con-cerning the degree of purity of collagen, since it is ex-tracted from natural products, and is difficult to produce in high purity. However, collagen can be made with a high 10 degree of purity, so that complications can be avoided when using it for surgical purposes.
DE-OS 28 43 963 describes a shaped mass resorbable in the body, on the basis of collagen. This shaped mass contains, in addition to denatured collagen, a bioresorbable binding 15 agent as well as optionally an active ingredient. The above-mentioned polymers and copolymers o-F glvcolic acid or of lac-tide and glycolide are especially s~itable as the bioresor-bable binding agents.
It is the object of this invention to provide a bioresorbable 20 implant containing an active ingredient for im~lantation in bones or soft tissues.
This object has been attained by providing a very ~ure nati-`
ve collagen containing an acti~e ingredient, and having a factor nitrogen:hydroxyproline~ 3 to 5 in the form of a sheet 25 or rod, the rod beinq made by rolling the collagen sheet.
(By the term "native collagen" is ment collagen which is purified but not changed in its structure.) -The rod-shaped collaaen product has about the same thickness as a pencil. It can be conveniently made by adding a solu-30 tion of the active ingredient to a collagen solution; after ., drying, e.g. with hot air or by lyo~hilization, the colla-gen is first prepared in sheet Eorm ~as a so-called fascia).
Also the reverse route, depending on the stability of the active ingredient, can be undertaken, by first preparing the collagen fascia and then charginy it with the active ingredient. This can be done e.g. by spraying an aqueous so-lution of an active ingredient, e.g. an antibiotic in the iorm of a salt on the collagen sheet and allowing it to dry there. Equally it is possible to apply the antibio-tic or another pharmacologically e~fective compound, bypainting, rolling, dipping or sprinkling with an active in-gredient in powder form or in a similar manner. The so ob-tained collagen sheet charged with the acti~e ingredient can then be rolled into a rod-shaped product of about pencil thickness. In this form it can be cut into anv desired length depending on the desired dose and can be packed to remain sterile until used.
Especially suitable active ingredients in combination with collagen are aminoglycoside antibiotics, such as gentamycin. In salt form, e.g. as sulfate, gentamycin is water-soluble and can be added to the collagen in a wide ran~e from about 1 to about 100 mg/cm2 fascia or it can ~e sprayed on. The collagen sheet (collagen fascia) containing the gentamycin can then be rolled and dried and thereafter it maintains its rod-shape.
Other active ingredients such as sulfonamides, antise~tics, or corticosteroids can be added instead of or in addition to the antibiotic.
The collagen used has a purity expressed by the factor nit-rogen:hydroxyproline ~ 3 to 5. Such a collagen can be pre-pared in the manner described in the example.
Using the rod-sha~ed collagen charaed with an active in-7, ~
gredient of the invention is of special a~vantaye in -tha-t the active lngredlent adheres very well to the collagen and optionally can even be bonded to it. To the extent that the collagen decomposes over a period of time, the active ingredient is released~ so tha-t there is a sustained re-lease A further advantage is that the carrier matrix collagen serves as a guide for proliferating con-nective tissue cells and thus promotes the healing of the wound in a known manner.
~xample The following highly pure native collagen is prepared as follows:
Fresh beef tendons freed from all pigment layers and res-idues of muscle were homogenised and an amount correspon-ding to 100 g dry weight was extracted with 3 liters 0.05 Mcitrate buffer (pH 3.7) for 24 hours and then dialysed~for 12 hours against 1% acetic acid. Ihe tissue, suspended in 3 liters 1% acetic acid, was incubated with constant stir-ring for 48 hours at 15C with pepsin in a ratio of collagen to pepsin of 50 : 1.
The preparation was diluted with 1% acetic acid to 5 liters and then freed from undissolved tendon fragments by centri-fugation.
The viscous collagen solution was diaIysed against alkalised tap water (p~ 8.0) and wasthen vigorously centrifuged. The residue was again dissolved in 5 liters 1% acetic acid and dialysed. This process was repeated until the factor nitro-gen:hydroxv~roline was ~ 3. After the last dialysis a 1.5%
collagen solution in 0.05% acetic acid was prepared.
'7~6 Preparation of the Collagen Implant containing Active In-gredient 10 ml of the 1.5~ collagen solution obtained as above are placed in a dish of 10 x 10 cm. 100 ma gentamycin tin the 5 form of its sulfate) were added thereto. The solution was then lyophilized in the dish to yield a sponge-like mass having the shape of the dish. This sponge was then pressed into a fascia or sheet and optionally rolled into a rod-shaped product of pencil thickness.
10 The gentamycin-containing implant ohtained in this way was sterile-packed and sterilised with ethylene oxide in known manner.
Use If the above-mentioned collagen implant containing 100 mg 15 c,tentamycin is introduced into the tibia, it is completely resorbed there within 3 weeks. During this time the genta-mvcin is released.
,,~ ,
Collagen Implant Containing Active Ingredient(s) for Implantation in Bones or Soft Tissues and Process for its Manufacture The invention concerns an implant resorbable in the body and 5 containing active ingredients, for implantation in bones and soft tissues. It especially relates to a collagen implant ln the form of a sheet containing active ingredient(s), which optionally c~n be rolled into a rod and which after implan-tation in the bone or tissue gradually releases the ingre-10 dient(s).
It is known that collagen can be used as material which isbioresorbable in the body, for filling defects in bones or in soft tissues.
The use of polyhydroxy acetic acid ester for the manufacture 15 of antibiotic-containing resorbable surgical materials, e.g.
tubes, is known from DE-PS 12 93 396. DE-OS 20 51 ~ des-cribes a combination of an active ingredient with a polylac-tide or of a copolymer of lactide and glycolide units.
The above-mentioned materials are synthetic polymers or co-20 polymers which are decomposed in the body. Such polymers and copolymers have increasingly gained in significance because as fully synthetic products they have readilly re-producible properties and can be prepared in high purity.
;.... .
Materials of the above-mentioned polymers and copolymers are also used as synthetic resorbable suture materials.
For many years collagen has been known as a resorbable ma-terial and has been used hemostatically, especially during 5 and a~ter surgical operations or to fill body cavities or to cover wounds. There have always been certain problems con-cerning the degree of purity of collagen, since it is ex-tracted from natural products, and is difficult to produce in high purity. However, collagen can be made with a high 10 degree of purity, so that complications can be avoided when using it for surgical purposes.
DE-OS 28 43 963 describes a shaped mass resorbable in the body, on the basis of collagen. This shaped mass contains, in addition to denatured collagen, a bioresorbable binding 15 agent as well as optionally an active ingredient. The above-mentioned polymers and copolymers o-F glvcolic acid or of lac-tide and glycolide are especially s~itable as the bioresor-bable binding agents.
It is the object of this invention to provide a bioresorbable 20 implant containing an active ingredient for im~lantation in bones or soft tissues.
This object has been attained by providing a very ~ure nati-`
ve collagen containing an acti~e ingredient, and having a factor nitrogen:hydroxyproline~ 3 to 5 in the form of a sheet 25 or rod, the rod beinq made by rolling the collagen sheet.
(By the term "native collagen" is ment collagen which is purified but not changed in its structure.) -The rod-shaped collaaen product has about the same thickness as a pencil. It can be conveniently made by adding a solu-30 tion of the active ingredient to a collagen solution; after ., drying, e.g. with hot air or by lyo~hilization, the colla-gen is first prepared in sheet Eorm ~as a so-called fascia).
Also the reverse route, depending on the stability of the active ingredient, can be undertaken, by first preparing the collagen fascia and then charginy it with the active ingredient. This can be done e.g. by spraying an aqueous so-lution of an active ingredient, e.g. an antibiotic in the iorm of a salt on the collagen sheet and allowing it to dry there. Equally it is possible to apply the antibio-tic or another pharmacologically e~fective compound, bypainting, rolling, dipping or sprinkling with an active in-gredient in powder form or in a similar manner. The so ob-tained collagen sheet charged with the acti~e ingredient can then be rolled into a rod-shaped product of about pencil thickness. In this form it can be cut into anv desired length depending on the desired dose and can be packed to remain sterile until used.
Especially suitable active ingredients in combination with collagen are aminoglycoside antibiotics, such as gentamycin. In salt form, e.g. as sulfate, gentamycin is water-soluble and can be added to the collagen in a wide ran~e from about 1 to about 100 mg/cm2 fascia or it can ~e sprayed on. The collagen sheet (collagen fascia) containing the gentamycin can then be rolled and dried and thereafter it maintains its rod-shape.
Other active ingredients such as sulfonamides, antise~tics, or corticosteroids can be added instead of or in addition to the antibiotic.
The collagen used has a purity expressed by the factor nit-rogen:hydroxyproline ~ 3 to 5. Such a collagen can be pre-pared in the manner described in the example.
Using the rod-sha~ed collagen charaed with an active in-7, ~
gredient of the invention is of special a~vantaye in -tha-t the active lngredlent adheres very well to the collagen and optionally can even be bonded to it. To the extent that the collagen decomposes over a period of time, the active ingredient is released~ so tha-t there is a sustained re-lease A further advantage is that the carrier matrix collagen serves as a guide for proliferating con-nective tissue cells and thus promotes the healing of the wound in a known manner.
~xample The following highly pure native collagen is prepared as follows:
Fresh beef tendons freed from all pigment layers and res-idues of muscle were homogenised and an amount correspon-ding to 100 g dry weight was extracted with 3 liters 0.05 Mcitrate buffer (pH 3.7) for 24 hours and then dialysed~for 12 hours against 1% acetic acid. Ihe tissue, suspended in 3 liters 1% acetic acid, was incubated with constant stir-ring for 48 hours at 15C with pepsin in a ratio of collagen to pepsin of 50 : 1.
The preparation was diluted with 1% acetic acid to 5 liters and then freed from undissolved tendon fragments by centri-fugation.
The viscous collagen solution was diaIysed against alkalised tap water (p~ 8.0) and wasthen vigorously centrifuged. The residue was again dissolved in 5 liters 1% acetic acid and dialysed. This process was repeated until the factor nitro-gen:hydroxv~roline was ~ 3. After the last dialysis a 1.5%
collagen solution in 0.05% acetic acid was prepared.
'7~6 Preparation of the Collagen Implant containing Active In-gredient 10 ml of the 1.5~ collagen solution obtained as above are placed in a dish of 10 x 10 cm. 100 ma gentamycin tin the 5 form of its sulfate) were added thereto. The solution was then lyophilized in the dish to yield a sponge-like mass having the shape of the dish. This sponge was then pressed into a fascia or sheet and optionally rolled into a rod-shaped product of pencil thickness.
10 The gentamycin-containing implant ohtained in this way was sterile-packed and sterilised with ethylene oxide in known manner.
Use If the above-mentioned collagen implant containing 100 mg 15 c,tentamycin is introduced into the tibia, it is completely resorbed there within 3 weeks. During this time the genta-mvcin is released.
,,~ ,
Claims (11)
1. Collagen implant containing active ingredient(s) for implantation in bones or soft tissues, character-ized in that highly pure native collagen having a factor nitrogen:hydroxyproline ? 3 to 5 is charged with an active ingredient and optionally is rolled into a rod-shaped product.
2. Collagen implant according to claim 1, charac-terized in that the collagen is in sheet form which optionally is rolled into a rod-shaped product.
3. Collagen implant containing active ingredient(s) according to claim 1 characterized in that it is pre-pared by admixing the active ingredient(s) in a suit-able vehicle with a collagen solution and processing after drying into a sheet and then rolling the sheet into a rod.
4. Collagen implant containing active ingredient(s) according to claim 2 characterized in that it is pre-pared by admixing the active ingredient(s) in a suit-able vehicle with a collagen solution and processing after drying into a sheet and then rolling the sheet into a rod.
5. Collagen implant containing active ingredient(s) according to any one of claims 1 to 3, characterized in that the active ingredient is an antibiotic.
6. Collagen implant containing active ingredient(s) according to any one of claims 1 to 3, characterized in that the active ingredient is gentamycin.
7. Collagen implant containing active ingredient(s) according to claim 4, characterized in that the active ingredient is an antibiotic.
8. Collagen implant containing active ingredient(s) according to claim 4, characterized in that the active ingredient is gentamycin.
9. Collagen implant containing active ingredient(s) for implantation in bones or soft tissues, charac-terized in that it has been prepared by mixing a solution of highly pure native collagen having a factor nitrogen : hydroxyproline ? 3 to 5 with a solution or suspension of the active ingredient(s), lyophylizing said mixture and pressing the so obtained sponge-like mass into a sheet or drying said mixture with warm air, and rolling the so obtained sheet into a rod-shaped product.
10. Collagen implant according to claim 9, charac-terized in that the active ingredient is gentamycin.
11. Process for the preparation of a collagen implant containing active ingredient(s) according to claim 1, characterized in that highly pure native collagen having a factor nitrogen : hydroxyproline ? 3 to 5 is charged with active ingredient(s), processed into a sheet and optionally rolled into a rod.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19813124981 DE3124981A1 (en) | 1981-06-25 | 1981-06-25 | ACTIVE INGREDIENT COLLAGEN INSERT FOR INSERTION INTO BONES OR SOFT PARTS AND METHOD FOR THEIR PRODUCTION |
| DEP3124981.7 | 1981-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1183776A true CA1183776A (en) | 1985-03-12 |
Family
ID=6135358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000406019A Expired CA1183776A (en) | 1981-06-25 | 1982-06-25 | Collagen implant containing active ingredient(s) for implantation in bones or soft tissues and process for its manufacture |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0069260B1 (en) |
| JP (1) | JPS584551A (en) |
| AT (1) | ATE15763T1 (en) |
| AU (1) | AU555952B2 (en) |
| CA (1) | CA1183776A (en) |
| DE (2) | DE3124981A1 (en) |
| IE (1) | IE53579B1 (en) |
| MX (1) | MX9203310A (en) |
| NZ (1) | NZ201067A (en) |
| ZA (1) | ZA824517B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863444A (en) * | 1985-09-19 | 1989-09-05 | Bloemer Alois | Antibiotic-containing agent and its use as a surgical plastic material |
| US5447966A (en) * | 1988-07-19 | 1995-09-05 | United States Surgical Corporation | Treating bioabsorbable surgical articles by coating with glycerine, polalkyleneoxide block copolymer and gelatin |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3409372A1 (en) * | 1984-03-14 | 1985-09-19 | Dr. Ruhland Nachf. GmbH, 8425 Neustadt | Material for the vitalisation of implant surfaces |
| DE3500268A1 (en) * | 1985-01-05 | 1986-07-10 | Hoechst Ag, 6230 Frankfurt | PREPARATIONS WITH DELAYED EFFECT, METHOD FOR THE PRODUCTION THEREOF AND CORRESPONDING AGENTS FOR THE HUMAN OR. VETERINE MEDICAL APPLICATION |
| US4865602A (en) * | 1986-11-06 | 1989-09-12 | Collagen Corporation | Gamma irradiation of collagen/mineral mixtures |
| NL8701370A (en) * | 1987-06-12 | 1987-08-03 | Stichting Surgical Research Fo | Chamois leather as an adhesive for living tissues. |
| AP105A (en) * | 1987-12-11 | 1990-11-07 | Geo Schwulst Laboratories Ltd | Treatment of animals. |
| US4975526A (en) * | 1989-02-23 | 1990-12-04 | Creative Biomolecules, Inc. | Bone collagen matrix for zenogenic implants |
| US6586388B2 (en) | 1988-04-08 | 2003-07-01 | Stryker Corporation | Method of using recombinant osteogenic protein to repair bone or cartilage defects |
| US5162114A (en) * | 1989-02-23 | 1992-11-10 | Stryker Corporation | Bone collagen matrix for xenogenic implants |
| US5266683A (en) * | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
| US5354557A (en) * | 1988-04-08 | 1994-10-11 | Stryker Corporation | Osteogenic devices |
| US6919308B2 (en) | 1988-04-08 | 2005-07-19 | Stryker Corporation | Osteogenic devices |
| US5645591A (en) | 1990-05-29 | 1997-07-08 | Stryker Corporation | Synthetic bone matrix |
| ATE139126T1 (en) * | 1990-09-10 | 1996-06-15 | Synthes Ag | MEMBRANE FOR BONE REGENERATION |
| DE9203684U1 (en) * | 1992-03-19 | 1992-07-02 | Pohl, Yango, 6350 Bad Nauheim, De | |
| IL105529A0 (en) * | 1992-05-01 | 1993-08-18 | Amgen Inc | Collagen-containing sponges as drug delivery for proteins |
| US5733884A (en) | 1995-11-07 | 1998-03-31 | Nestec Ltd. | Enteral formulation designed for optimized wound healing |
| DE19739031A1 (en) * | 1997-09-05 | 1999-03-11 | Suwelack Nachf Dr Otto | Oral administration agent, its preparation and use |
| DE19962248A1 (en) | 1999-12-22 | 2001-06-28 | Tutogen Medical Gmbh | Producing bone material containing bone morphogenic protein, useful as transplant for accelerating bone growth, includes resorbable material for sustained release of protein |
| USRE47826E1 (en) | 2007-03-28 | 2020-01-28 | Innocoll Pharmaceuticals Limited | Drug delivery device for providing local analgesia, local anesthesia or nerve blockage |
| US8034368B2 (en) | 2007-03-28 | 2011-10-11 | Innocoll Technologies Limited | Drug delivery device for providing local analgesia, local anesthesia or nerve blockage |
| JP5945380B2 (en) * | 2008-12-09 | 2016-07-05 | Hoya株式会社 | Absorption-replacement type artificial bone and manufacturing method thereof |
| GB2468941B (en) * | 2008-12-26 | 2013-02-27 | Hoya Corp | Artifical bone capable of being absorbed and replaced by autogenous bone and its production method |
| EP2510929A1 (en) * | 2011-04-11 | 2012-10-17 | Innocoll Technologies Limited | Methods for treating bacterial infection |
| WO2013045689A1 (en) | 2011-09-29 | 2013-04-04 | BIORIGEN Srl | Therapeutic use of gelatin hydrogels with a gel-sol transition at body temperature |
| EP2574349A1 (en) | 2011-09-29 | 2013-04-03 | Biorigen S.r.l | Therapeutic use of gelatin hydrogels with a gel-sol transition at body temperature |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3625214A (en) * | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
| US3949073A (en) * | 1974-11-18 | 1976-04-06 | The Board Of Trustees Of Leland Stanford Junior University | Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution |
| CH627078A5 (en) * | 1975-06-05 | 1981-12-31 | Pentapharm Ag | Process for the preparation of a sterile collagen product with felt-like or web-like fibre structure |
| JPS5842473B2 (en) * | 1975-09-02 | 1983-09-20 | シャープ株式会社 | Hakumaku EL Soshino Kudohouhou |
| SU736374A1 (en) * | 1977-06-06 | 1980-05-25 | Предприятие П/Я Р-6517 | Method and device for dc cutout |
| DE2815934A1 (en) * | 1978-04-13 | 1979-10-25 | Merck Patent Gmbh | Surgical pegs for insertion into bone - consisting of a plastic and an antibacterial e.g. gentamycin |
| GB1565340A (en) * | 1978-04-25 | 1980-04-16 | Grant R A | Fibrous tussue preparations |
| DE2854490C2 (en) * | 1978-12-16 | 1981-04-09 | B. Braun Melsungen Ag, 3508 Melsungen | Bone substitute material with improved biological stability based on collagen |
| US4279812A (en) * | 1979-09-12 | 1981-07-21 | Seton Company | Process for preparing macromolecular biologically active collagen |
-
1981
- 1981-06-25 DE DE19813124981 patent/DE3124981A1/en not_active Withdrawn
-
1982
- 1982-06-18 EP EP82105341A patent/EP0069260B1/en not_active Expired
- 1982-06-18 AT AT82105341T patent/ATE15763T1/en not_active IP Right Cessation
- 1982-06-18 DE DE8282105341T patent/DE3266525D1/en not_active Expired
- 1982-06-24 IE IE1514/82A patent/IE53579B1/en not_active IP Right Cessation
- 1982-06-24 NZ NZ201067A patent/NZ201067A/en unknown
- 1982-06-24 ZA ZA824517A patent/ZA824517B/en unknown
- 1982-06-24 AU AU85177/82A patent/AU555952B2/en not_active Expired
- 1982-06-25 JP JP57109695A patent/JPS584551A/en active Granted
- 1982-06-25 CA CA000406019A patent/CA1183776A/en not_active Expired
-
1992
- 1992-06-25 MX MX9203310A patent/MX9203310A/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863444A (en) * | 1985-09-19 | 1989-09-05 | Bloemer Alois | Antibiotic-containing agent and its use as a surgical plastic material |
| US5447966A (en) * | 1988-07-19 | 1995-09-05 | United States Surgical Corporation | Treating bioabsorbable surgical articles by coating with glycerine, polalkyleneoxide block copolymer and gelatin |
Also Published As
| Publication number | Publication date |
|---|---|
| MX9203310A (en) | 1992-07-01 |
| EP0069260A2 (en) | 1983-01-12 |
| ATE15763T1 (en) | 1985-10-15 |
| NZ201067A (en) | 1985-05-31 |
| DE3266525D1 (en) | 1985-10-31 |
| ZA824517B (en) | 1983-04-27 |
| AU555952B2 (en) | 1986-10-16 |
| JPS584551A (en) | 1983-01-11 |
| IE53579B1 (en) | 1988-12-21 |
| IE821514L (en) | 1982-12-25 |
| EP0069260B1 (en) | 1985-09-25 |
| JPH0118744B2 (en) | 1989-04-07 |
| DE3124981A1 (en) | 1983-01-13 |
| AU8517782A (en) | 1983-01-06 |
| EP0069260A3 (en) | 1983-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1183776A (en) | Collagen implant containing active ingredient(s) for implantation in bones or soft tissues and process for its manufacture | |
| US5149368A (en) | Resorbable bioactive calcium phosphate cement | |
| US4917702A (en) | Bone replacement material on the basis of carbonate and alkali containing calciumphosphate apatites | |
| US5433751A (en) | Bone prosthesis material containing calcium carbonate particles dispersed in a bioresorbable polymer matrix | |
| EP0987032B1 (en) | Ceramic material for osteoinduction comprising micropores in the surface of macropores | |
| US6214048B1 (en) | Bone substitute product and method of producing the same | |
| JPH07171211A (en) | Bone substitution material charged with fibroblast growth factor | |
| US5374427A (en) | Implantable active substance depot material | |
| IE782393L (en) | Absorbable hemostatic composition | |
| JP2004528904A (en) | Calcium phosphate / sulfate based bone implant composition | |
| US5755787A (en) | Semi-synthetic material usable in medicine and surgery | |
| JP2003501217A (en) | Biomaterials based on insolubilized dextran derivatives and growth factors | |
| EP1047459A1 (en) | Implant made of a reabsorbable ceramic material | |
| US5147904A (en) | Open-pored moldings, a process for their production and use thereof | |
| CA2004166C (en) | Implant for use in bone surgery | |
| EP0321442B1 (en) | Biologically absorbable implant material, and method for its preparation | |
| EP1306390B1 (en) | Method of producing low molecular weight chitin/chitosan and method of producing an osteoconduction substance | |
| EP0429419A3 (en) | Implant material composition, preparation thereof as well as uses thereof and implant product obtainable therefrom | |
| JPH04348754A (en) | Slowly drug-releasable calcium phosphate cement | |
| JPS60106459A (en) | Calcium phosphate filler | |
| Rønningen et al. | Osteogenesis promoted by bone matrix combined with marrow: Titanium implants studied in rats | |
| Kuru et al. | Design of Injectable Pre-Mixed Dental Putty for Bone Regeneration Applications in Dentistry | |
| Katthagen et al. | Bone-Replacement Materials | |
| EP0652016A1 (en) | Resorbable and radiosterilisable intramedullary or diaphysary or blocking plugs | |
| Morales et al. | Etude expérimentale de languettes de plâtre imprégnées de Gentamicine® |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEC | Expiry (correction) | ||
| MKEX | Expiry |